Back to results
US 2023/0203536 A1Published application
Coronavirus rna replicons and use thereof as vaccines
AssigneeConsejo Superior De Investigaciones Cientificas (Csic)
InventorsLuis ENJUANES SÁNCHEZ, María Isabel SOLA GURPEGUI, Sonia ZÚÑIGA LUCAS, Francisco Javier GUTIÉRREZ ÁLVAREZ, José Manuel HONRUBIA BELENGUER, Raúl FERNÁNDEZ DELGADO
Life of this patent
Estimating the term…
Abstract
RNA replicon derived from a coronavirus with complete or partial deletion of: the gene encoding the E protein and at least 4 genes encoding genus accessory proteins selected from: 3, 4a, 4b and 5, in the case of MERS-CoV. Method of preparation thereof, and their use in vaccine compositions.
Claims26
An RNA replicon derived from a coronavirus to which it has been deleted comprising:
- partially the gene encoding the E protein retaining the last 52 nucleotides of the sequence of this gene and
- total or partially at least 4 genes encoding genus accessory proteins selected from 3, 4a, 4b and 5 of MERS CoV retaining 39 nucleotides of the sequence of the gene encoding genus accessory protein 3, said 39 nucleotides are located in position 33409-33447 of SEQ_ID 1, and
- an identity of at least 95% or 96% or 97% or 98% or 99% with respect to the sequence SEQ_ID 1, namely with respect to the fragment comprised from nucleotides 7890 to 35838.
-8. (canceled)
-11. (canceled)
-14. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.